

From Suzuki-Miyaura cross coupling reactions of 2-/4-haloestranes to fluorinated benzofuranoestranes

Christian Burmester,¹ Kodai Shiine,² Shuntaro Mataka,¹ Thies Thiemann^{2,3*}

¹Institute of Materials Chemistry and Engineering and

²Interdisciplinary Graduate School of Engineering Sciences,
Kyushu University, 6-1, Kasuga-koh-en, Kasuga-shi, 816-8580, Japan

³Present address: College of Science, United Arab Emirates University, Al Ain, United Arab Emirates.




Figure 1

16,17-areno annelated estrane derivatives, previously prepared by the group.
Applications are found as ligands to the estrogen receptor and as chiral dopants in organic materials .




Figure 2

Target structures of this work





Figure 3 A-ring furano-annelated estranes, published by other groups




No.	X	Fn
13a	O	2,5-F (21%)
13b	O	2,3-F (3%)
13c	OH	2,4-F

No.	X	Fn--1
14a	O	5-F (9%)
14b	O	3-F (84%)
14c	OH	4-F (16%)

Scheme 1

Selective bromination of the estradiol derivative at C4 with NBS, DMF is followed by an arylation through a Suzuki-Miyaura reaction utilizing arylboronic acids bearing a 2-fluoro substituent. Subsequent *ipso*-substitution of the 2-fluoro substituent by the phenoxy group gives the benzofuranoestranes **14**.



No.	X	Fn
17a	O	2,3-F (64%)
17b	OH	2,4-F (75%)
17c	OH	2-F (49%)
17d	OH	4-F (77%)
17e	OH	4-CF ₃ (63%)
17f	OH	4-OMe (66%)

No.	X	Fn--1
18a	O	3-F (35%)
18b	OH	4-F (80%)

Scheme 2

The authors were not able to carry out iodination selectively at C2 or C4. Rather, iodination of 3-OH non-protected estranes led to double iodination at C2 and at C4, such as found in **15**. The Suzuki coupling, however, could be performed with **15** selectively at C2. At the same time, deiodination occurred at C4 to give compounds **17**. These could also be produced by reaction with 2-bromoestrone/estradiol. Cyclization led to benzofuranoestrans **18**.

Literature

1. T. Thiemann, M. Watanabe, S. Mataka, *New J. Chem.*, **2001**, 25, 1104 – 1107.
2. M. das Neves Oliveira, M. Videira, A. Almeida, L. Gano, M. Watanabe, T. Thiemann, A. C. Santos, M. Botelho, C. Oliveira, *J. Labelled Compd. Radiopharm.*, **2006**, 49, 559 – 569.
3. M. Watanabe, S. Mataka, T. Thiemann, *Steroids*, **2005**, 70, 856 – 866;
4. 4a. T. Matsumoto, M. Watanabe, S. Mataka, T. Thiemann, *Steroids*, **2003**, 68, 751 – 757; 4b. T. Matsumoto, K. Shiine, S. Mataka, T. Thiemann, *J. Chem. Res.*, **2009**, 33, 391 – 396; 4c. T. Matsumoto, T. Matsumoto, M. Watanabe, S. Mataka, T. Thiemann, *Acta Cryst., Sect. C*, **2004**, C60, o501 – o502.
5. 5a. A. Jefferson, F. Scheinmann, *J. Chem. Soc., Chem. Commun.*, **1966**, 239 – 240; 5b. A. Jefferson, F. Scheinmann, *J. Chem. Soc., Sect. C*, **1969**, 243 – 245.
6. A. M. M. E. Omar, O. M. Aboulwafa, I. M. Labouta, A. A. A. El-Tombary, A. I. El-Mallah, *Arch. Pharm.*, **1996**, 329, 61 – 65.
7. H. G. Lehmann, *Tetrahedron Lett.*, **1968**, 607 – 608.
8. B. Xiao, T.-J. Gong, Z.-S. Liu, J. H. Liu, B.-F. Luo, J. Xu, L. Liu, *J. Am. Chem. Soc.*, **2011**, 133, 9250 – 9253.